Factor V from Human Plasma

Douglas M. Surgenor; Nancy A. Wilson; Anne S. Henry

doi:10.1055/s-0038-1654899

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1961; 05(01): 001-020
DOI: 10.1055/s-0038-1654899

Originalarbeiten – Original Article – Travaux Originaux

Schattauer GmbH

Factor V from Human Plasma

Authors

Douglas M. Surgenor

¹Department of Biological Chemistry, Harvard Medical School and the Protein Foundation, Boston, Massachusetts, USA
Nancy A. Wilson

¹Department of Biological Chemistry, Harvard Medical School and the Protein Foundation, Boston, Massachusetts, USA
Anne S. Henry

¹Department of Biological Chemistry, Harvard Medical School and the Protein Foundation, Boston, Massachusetts, USA

Abstract

Summary

A method is described for the partial purification of a human plasma factor which accelerates the conversion of prothrombin to thrombin in the presence of tissue thromboplastin. This factor may be dried from the frozen state, and may be kept in stable dry form for long periods of time. The quantitative assay of this activity is done in a classical two-stage prothrombin system using tissue thromboplastin and calcium. From its properties, it is concluded that this activity corresponds to factor V, labile factor and plasma Ac-globulin.

Chemical and kinetic studies reveal that human factor V is active in plasma and is destroyed by thrombin. Human serum has little or no factor V activity.

These results thus fail to support the postulated activation of factor V during clotting. All of the kinetic data are consistent with an enzymatic role for factor V in the formation of tissue prothrombin activator (thromboplastin).

Full Text

References

References
1 Nolf P. Contribution a l’Etude de la Coagulation du Sang. Arch. Int. Physiol. 06: 1 1908;
2 Quick A. J. On the constitution of prothrombin. Amer. J. Physiol. 140: 212 1943;
3 Fanll P, Nance M. H. Accelerator of thrombin formation by a plasma component. Nture 158: 708 1946;
4 Owren P. A. The coagulation of blood. Investigations on a new clotting factor. Acta med. scand. Suppl. 194 1947;
5 Ware A. G, Murphy R. C, Seegers W. H. The function of Ac-Globulin in blood clotting. Science 106: 618 1947;
6 Astrup T. Blood clotting and related processes. Adv. in Enzymology F, Nord F. Ed. Interscience Publishers; New York: 1950
7 Owren P. A. The fifth coagulation factor (“Factor V”). Preparation and properties. Biochem. J. 43: 136 1948;
8 Ware A. G, Seegers W. H. Plasma accelerator globulin: partial purfication, quantitative determination, and properties. J. biol. Chem. 172: 699 1948;
9 Ware A. G, Seegers W. H. Serum Ac-Globulin: Formation from Plasma Ac-Globulin, role in blood coagulation; partial purification; properties; and quantitative determination. Amer. J. Physiol. 152: 567 1948;
10 Lewis M. L, Ware A. G. A simple procedure for separation of prothrombin and accelerator globulin from citrated human plasma. Proc. Soc. Exp. Biol. (N. Y) 84: 636 1953;
11 Cox F. F, Lanchantin G. F, Ware A. G. Chromatographic purification of human serum accelerator globulin. J. clin. Invest 35: 106 1956;
12 Biggs R, MacFarlane R. E. Human Blood Coagulation. 2nd Ed.. 391 Blackwell; Oxford: 1957
13 Cohn E. J, Gurd F. R. N, Surgenor D. M, Barnes B. A, Brown R. K, Derouaux G, Gillespie J. M, Kahnt F. W, Lever W. F, Liu C. H, Mittelman D, Mouton R. F, Schmid K, Uroma E. A system for the separation of the components of human blood: Quantitative procedures for the separation of the protein components of human plasma. J. Amer. chem. Soc. 72: 465 1950;
14 Surgenor D. M, Alexander B, Goldstein R, Schmid K. A system for the separation of the protein components of human plasma. II. The components of the clotting process. J. Phys. Coll. Chem. 55: 94 1951;
15 Surgenor D. M, Pennell R. B, Alameri E, Batchelor W. H, Brown R. K, Hunter M. J. Preparation and properties of serum and plasma proteins. XXXV. A system of protein fractionation using zinc complexes. Vox sanguinis. in press..
16 Cohn E. J, Strong L. E, Hughes Jr W. L, Ashworth J. N, Mul-ford D. J, Melin M, Taylor H. L. Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J. Amer. chem. Soc. 68: 459 1946;
17 Surgenor D. M, Steele B. B, Wallach D. F. H. Thrombin formation in purified systems. Thromb. Diath. haem. 03: 214 1959;
18 Wallach D. F. H, Surgenor D. M. In: preparation.
19 Johnson J. F, Seegers W. H. The Coagulation of Blood. Tocantins L. M. Ed. 127 Greene and Stratton; New York: 1955
20 Surgenor D. M, McMillan C. W, Diamond L. K, Steele B. B. Studies with AHF-rich fibrinogen in classical hemophilia. Vox Sanguinis 05: 80 1960;
21 Tullis J. L, Surgenor D. M, Tinch R. J, D’Hont M, Gilchrist F. L, Driscoll S, Batchelor W. H. New principle of closed centrifugation Science. 124: 3226 1956;
22 Pyle H, Tullis J. L, Penell R. B. Observations on donor variability during plasmapheresis. Vox Sanguinis 04: 70 1959;
23 Surgenor D. M, Melin M, Henry A. S, Wheaton L. P, Wilson N. A, Tullis J. L. Preparation of Factor V for clinical use. Vox Sanguinis 05: 77 1960;
24 Surgenor D. M, Melin M, Steele B. B, Wheaton L, Pennell R. B. Preparation of barium sulfate eluate from plasma for physiological studies in humans. Vox Sanguinis 04: 71 1959;
25 Oncley J. L, Melin M, Richert D. A, Cameron J. W, Gross P. The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and ß_rlipo- protein into subfractions of human plasma. J. Amer. chem. Soc. 71: 541 1949;
26 Gurd F. R. N. Effect of temperature on the interaction of human serum mercapt- albumin with zinc ions. J. Phys. Chem. 58: 788 1954;
27 Cohn E. J, Surgenor D. M, Schmid K, Batchelor W. H, Isliker H. A, Alameri E. H. The interaction of plasma proteins with heavy metals and with alkaline earths, with specific anions and specific steroids, with specific polysaccharides and with the formed elements of the blood. Faraday Society Discussion 13: 176 1953;
28 Fanti P. Parahemophilia (Proaccelerin Deficiency): Occurrence and Biochemistry. Chapter in Hemophilia and Hemophilioid Diseases. Brinkhous K. Ed. 79 University of North Carolina Press; Chapel Hill: 1957
29 Owren P. A. Prothrombin accessory factors. Clinical significance. Amer. J. Med. 14: 201 1953;
30 Johnson J. F, Seegers W. H. Techniques in Blood Coagulation Used at Wayne University. Detroit: Michigan; 1953
31 Alexander B. A, Goldstein R, Landwehr G. The prothrombin conversion accelerator of serum (SPCA): Its partial purification and its properties compared with Serum Ac-Globulin. J. clin. Invest 29: 881 1950;
32 Koller F, Loeliger A, Duckert F. Experiments on a new clotting factor (Factor VII). Acta Haem. 06: 1 1951;
33 Lewis M. L, Ware A. G. The mechanism of action of human accelerator globulin and its relation to other clotting factors. Blood 09: 520 1954;
34 Wallach D. F. H, Maurice P. A, Steele B. B, Surgenor D. M. Studies on the relationship between the colloidal state and clot-promoting activity of pure phosphatidylethanolamines. J. Biol. Chem. 234: 2829 1959;
35 Surgenor D. M. Some properties of a reaction mechanism analogous to thrombin formation. Thromb. Diath. haem. 03: 227 1959;
36 erstraete V. M, Vanderbrouke J. The thromboplastin generation test. Acta med. scand. 155: 37 1956;
37 Johnston B. R, Jensen H. Role of plasma accelerator globulin and serum accelerator globulin in the conversion of prothrombin. Amer. J. Physiol. 194: 1 1958;